Healthcare Resource Utilization Associated With Venous Thromboembolism In Cancer Patients Treated With Anticoagulants In A Commercial Insurance Population

Introduction: Research among Medicare cancer patients shows healthcare resource use (HRU) associated with venous thromboembolism (VTE) treatment is lowest with rivaroxaban as compared to LMWH or warfarin (WAR); rivaroxaban is also associated with fewer re-hospitalizations due to VTE recurrence. This study analyzes HRU in younger cancer patients from a large commercial insurance claims database. Hypothesis: VTE-related HRU in cancer patients is lower with rivaroxaban than with LMWH or WAR in a commercial insurance claims database. Methods: Truven Health Analytics MarketScan databases were used to identify patients aged ≥18 newly diagnosed with cancer who then had first VTE (DVT or PE; excluding upper VTE) in 1/1/2013 - 9/30/2016 and anticoagulant (AC) initiation ≤7 days. Patients were put into LMWH, WAR, and rivaroxaban cohorts by index AC and followed to end of insurance eligibility or data. WAR users included those who started LMWH and WAR within 7 days. Inverse probability of treatment weights based on ...